Migraine News Highlights AJPB Week in Review

Article

Top news of the week from The American Journal of Pharmacy Benefits.

5. Immunotherapy Treatment Improves PFS in Advanced Triple-Negative Breast Cancer

Atezolizumab (Tecentriq) plus chemotherapy nab-paclitaxel (Abraxane) significantly reduced the risk of disease worsening or death in patients with metastatic triple-negative breast cancer. Read more.

4. Pain Societies Create Consensus Guidelines for Use of Ketamine in Pain Management

Three pain societies have come together to create consensus guidelines for treating both acute and chronic pain with ketamine, an old drug seeing a resurgence. Read more.

3. Coffee and Chocolate May Trigger Migraines

As researchers examined what food and drinks were most commonly linked to migraine and tension-type headache in Malaysian patients, they found that coffee and chocolate were reported most often. Read more.

2. Estrogen Levels May Play a Role in Migraine Prevalence in Men

A study of 39 men found that those affected by migraine had higher levels of estradiol, an estrogen, than those without migraine. Read more.

1. Trial Demonstrates Positive Long-Term Efficacy and Safety for Migraine Drug

Amgen and Novartis have announced positive long-term efficacy, safety, and tolerability data of erenumab-aooe (Aimovig) in patients with chronic and episodic migraine. Read more.

Related Videos
pharmacy oncology, Image Credit: © Konstantin Yuganov - stock.adobe.com
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Video 12 - "Collaborative Care: Key Stakeholders in HE Treatment and Recovery"
Video 11 - "Optimizing Transitions of Care for Hepatic Encephalopathy Patients"
Video 10 - "Valuable Metrics and Improving Adherence in Patients With ASCVD"
Video 9 - "The Role of Pharmacists in Treating Very High-Risk ASCVD"
Video 6 - "evaluating CDK4/6 inhibitor safety profiles"
Video 5 - "CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC"
Video 8 - "Challenges of Concurrent Administration: RSV and Other Vaccines "
© 2024 MJH Life Sciences

All rights reserved.